In this scenario, the role of the IL-6/STAT3 pathway may represent a target for innovative gastric cancer therapeutic strategies [28,33,34,35] often associated with clinically aggressive features and resistance to conventional therapy [44,45,46]. This evidence concerns the gene STAT3 and gastric cancer.